Companies / Japan
Japan's Tough Market To Separate Winners, Losers
May 2006 | Company Finance AlertHeavy spending on product in-licensing and imminent patent expiries are set to bring mixed fortunes for Japan's leading drugmakers, according to local observers. In the coming years, the success of operations in the US are also expected to be underpin continued sales growth.
Sorry, you must be a subscriber to view this article in full. If you are a subscriber please login.
If you would like to subscribe to Asia Pacific Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Asia Pacific Pharma & Healthcare Insight please click on the trial link below.
